just replying to myself & my incorrect math... inavir's infection rate is actually 4.9% (not 3.6%) compared to relenza's 4%.
4.9% vs 8.5% placebo = about 42% & a bit
using relenza's 19% placebo rate, the reduction would equate to 4.9% vs 19% placebo = 74% (not 81%)
Ann: Phase III prophylaxis trial for CS-8958 , page-42
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)